{
    "eid": "2-s2.0-84923785129",
    "title": "Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis",
    "cover-date": "2015-02-01",
    "subject-areas": [
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        },
        {
            "$": "Immunology",
            "@code": "2403"
        },
        {
            "$": "Epidemiology",
            "@code": "2713"
        },
        {
            "$": "Virology",
            "@code": "2406"
        }
    ],
    "keywords": [],
    "authors": [
        "Mark A. Boyd"
    ],
    "citedby-count": 68,
    "ref-count": 31,
    "ref-list": [
        "Guidelines for the use of antiretroviral agents in adults and adolescents",
        "Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia",
        "Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials",
        "Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials",
        "Raltegravir with optimized background therapy for resistant HIV-1 infection",
        "Maraviroc for previously treated patients with R5 HIV-1 infection",
        "Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study",
        "Assessment of second-line antiretroviral regimens for HIV therapy in Africa",
        "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach",
        "Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives",
        "Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: Implications for antiretroviral therapy programs in resource-limited settings",
        "The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy",
        "Genotypic Resistance Interpretation Algorithm version 6.3.1",
        "Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments",
        "Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia",
        "Implications of antiretroviral resistance on viral fitness",
        "Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection",
        "Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting",
        "Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline",
        "Viral suppression following switch to second-line antiretroviral therapy: Associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch",
        "Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study",
        "Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial",
        "Editorial commentary: HIV RNA and genotype in resource-limited settings: Can we do better?",
        "Limited benefit of antiretroviral resistance testing in treatment-experienced patients: A meta-analysis",
        "Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials",
        "Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the united states, 2009-2012",
        "Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial",
        "Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings",
        "Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study",
        "Update of the drug resistance mutations in HIV-1: March 2013"
    ],
    "affiliation": [
        {
            "affiliation-city": "North Chicago",
            "affilname": "AbbVie",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kensington",
            "affilname": "The Kirby Institute",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Santiago",
            "affilname": "Universidad de Chile",
            "affiliation-country": "Chile"
        },
        {
            "affiliation-city": "Tlalpan",
            "affilname": "Instituto Nacional de la Nutrici\u00f3n Salvador Zubiran",
            "affiliation-country": "Mexico"
        },
        {
            "affiliation-city": "Rahway",
            "affilname": "Merck &amp; Co., Inc.",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Paris",
            "affilname": "H\u00f4pital Saint-Louis",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Buenos Aires",
            "affilname": "Hospital J.M. Ramos Mejia, Buenos Aires",
            "affiliation-country": "Argentina"
        },
        {
            "affiliation-city": "Cape Town",
            "affilname": "University of Cape Town",
            "affiliation-country": "South Africa"
        }
    ],
    "funding": []
}